Alnylam Pharmaceuticals Inc logo

Alnylam Pharmaceuticals Inc - BRDR

BSP:A1LN34 (USA)   BRDR
R$ 38.63 (-2.05%) Feb 28
At Loss
Market Cap:
R$ 97.31B ($ 19.58B)
Enterprise V:
R$ 91.71B ($ 18.46B)
Volume:
1.00
Avg Vol (2M):
10.00
Also Trade In:
Volume:
1.00
At Loss

Business Description

Description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Name Current Vs Industry Vs History
Cash-To-Debt 1.87
Equity-to-Asset -0.06
Debt-to-Equity -5.92
Debt-to-EBITDA -6.06
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.17
Distress
Grey
Safe
Beneish M-Score -2.46
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 39.59
9-Day RSI 36.4
14-Day RSI 33.98
6-1 Month Momentum % 0.67
12-1 Month Momentum % -21.32

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.08
Quick Ratio 2.99
Cash Ratio 2.52
Days Inventory 128.46
Days Sales Outstanding 53.15
Days Payable 82.18

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.6
Shareholder Yield % -0.79

Financials (Next Earnings Date:2024-05-03 Est.)

BSP:A1LN34's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Alnylam Pharmaceuticals Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil R$) 9,071.363
EPS (TTM) (R$) -0.886
Beta -0.09
Volatility % 25.98
14-Day RSI 33.98
14-Day ATR (R$) 0.606793
20-Day SMA (R$) 40.397
12-1 Month Momentum % -21.32
52-Week Range (R$) 36.3 - 57.7
Shares Outstanding (Mil) 2,518.92

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Alnylam Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Alnylam Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price(R$)
No Event Data

Alnylam Pharmaceuticals Inc Frequently Asked Questions

What is Alnylam Pharmaceuticals Inc(BSP:A1LN34)'s stock price today?
The current price of BSP:A1LN34 is R$38.63. The 52 week high of BSP:A1LN34 is R$57.70 and 52 week low is R$36.30.
When is next earnings date of Alnylam Pharmaceuticals Inc(BSP:A1LN34)?
The next earnings date of Alnylam Pharmaceuticals Inc(BSP:A1LN34) is 2024-05-03 Est..
Does Alnylam Pharmaceuticals Inc(BSP:A1LN34) pay dividends? If so, how much?
Alnylam Pharmaceuticals Inc(BSP:A1LN34) does not pay dividend.

Press Release

Subject Date
No Press Release